FIELD: medicine.
SUBSTANCE: invention discloses a method of treating or controlling hypoparathyroidism in a patient, wherein the method includes the step of administering an initial dose of 4.4 ± 0.3 nmol/day of a parathyroid hormone (PTH) conjugate, in which the PTH moiety is reversibly conjugated to a polymer constituent or a pharmaceutically acceptable salt thereof, or the step of administering an initial dose of 4.4 ± 0.3 nmol/day of a pharmaceutical composition containing the said PTH conjugate or a pharmaceutically acceptable salt thereof, and wherein the PTH conjugate has the following formula (IIf-i), where the unlabeled dotted line shows the attachment to the N-terminal amine functionality of a PTH moiety having the following sequence SEQ ID NO: 51, due to the formation of an amide bond; and the dotted line marked with an asterisk shows the addition to the component where m and p independently represent an integer in the interval and including 400–500.
EFFECT: technical result of the invention is the reduction of side effects due to a safe and effective initial dose of a long-acting PTH conjugate.
6 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RTN PRODRUGS | 2017 |
|
RU2747316C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| STABLE LOCAL DRUG LEVELS FOR INNATE IMMUNITY AGONISTS | 2020 |
|
RU2817710C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| IL-2 CONJUGATES | 2019 |
|
RU2809259C2 |
| BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE | 2018 |
|
RU2780334C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
